Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Dose, Open-Label, Extension Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With Irritable Bowel Syndrome With Constipation

Next Previous
Trial Profile

A Single-Dose, Open-Label, Extension Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With Irritable Bowel Syndrome With Constipation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lovastatin (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Sponsors Synthetic Biologics; Theriva Biologics

Most Recent Events

  • 23 May 2016 According to a Synthetic Biologics media release, results from this trial were presented at Digestive Disease Week (DDW 2016).
  • 23 May 2016 Results published in a Synthetic Biologics media release.
  • 05 May 2016 Detailed data will be presented at the Digestive Disease Week 2016, according to a Synthetic Biologics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top